the cabinet
Drugs
8,127 products tracked
Phase 1
SKL-20540
Cognitive Impairment Associated With Schizophrenia (CIAS)
SK Life Science Inc
0 catalysts
Phase 1SKL-24741
Epilepsy
SK Life Science Inc
0 catalysts
SKYRIZI
SKYRIZI (RISANKIZUMAB-RZAA)
1 INDICATIONS AND USAGE SKYRIZI is an interleukin-23 antagonist indicated for…
Interleukin-23
$ABBVAbbVie Inc.
0 catalysts